托珠单抗对比安慰剂治疗不同临床表现的巨细胞动脉炎:GiACTA试验事后分析
该研究为GiACTA随机对照试验的事后分析,评估托珠单抗(TCZ)对基线表现为单纯风湿性多肌痛(PMR)症状、单纯颅部症状或两者兼有的巨细胞动脉炎(GCA)患者的疗效。结果显示,第52周时TCZ组在全部3组中持续缓解率均显著高于安慰剂组,且TCZ治疗患者疾病复发比例更低。
要点
- TCZ显著提高单纯PMR症状、单纯颅部症状及两者兼有GCA患者的持续缓解率。
- TCZ组疾病复发比例在全部3组中均低于安慰剂组。
- 单纯PMR症状组年化复发率和复发风险数值上更低但未达统计学显著。
核心结论
- TCZ可改善基线表现为单纯PMR症状、单纯颅部症状或两者兼有的GCA患者的临床结局,提示TCZ对GCA有效 regardless of presenting clinical phenotype。
研究设计与样本
- GiACTA试验的事后分析,纳入250例GCA患者,随机接受TCZ每周或每两周一次联合26周泼尼松减量,或安慰剂联合26周或52周泼尼松减量。
主要发现
- 第52周持续缓解率:单纯PMR症状组TCZ 45.2% vs 安慰剂 19.0%(P=0.0446);单纯颅部症状组60.3% vs 19.4%(P=0.0001);两者兼有组55.0% vs 11.4%(P<0.0001)。
- 疾病复发比例:单纯PMR症状组TCZ 41.9% vs 安慰剂 57.1%;单纯颅部症状组20.7% vs 47.2%;两者兼有组31.7% vs 81.8%。
- 年化复发率和复发风险在单纯颅部症状组和两者兼有组中TCZ显著低于安慰剂;在样本量较小的单纯PMR症状组中数值更低但未达统计学显著。
临床怎么用
- 对于GCA患者,无论基线表现为单纯PMR症状、单纯颅部症状还是两者兼有,均可考虑使用TCZ治疗以提升持续缓解率并降低复发风险。
局限性
- 本研究为事后分析,单纯PMR症状组样本量较小(52例),年化复发率和复发风险的差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The randomized, placebo (PBO)-controlled GiACTA trial demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA). The present study evaluated the efficacy of TCZ in patients with GCA presenting with polymyalgia rheumatica (PMR) symptoms only, cranial symptoms only or both PMR and cranial symptoms in the GiACTA trial. METHODS: In GiACTA, 250 patients with GCA received either TCZ weekly or every other week plus a 26-week prednisone taper or PBO plus a 26- or 52-week prednisone taper. This post hoc analysis assessed baseline characteristics, sustained remission rate, number of flares, annualized flare rate, time to flare, cumulative prednisone dose, methotrexate use and safety in patients with PMR symptoms only, cranial symptoms only or both at baseline. RESULTS: Overall, 52 patients had PMR symptoms only, 94 had cranial symptoms only and 104 had both symptoms at baseline. At Week 52, rates of sustained remission were significantly higher with TCZ vs PBO in all 3 groups (PMR only, 45.2% vs 19.0%, P = 0.0446; cranial only, 60.3% vs 19.4%, P = 0.0001; PMR and cranial, 55.0% vs 11.4%, P < 0.0001). Smaller proportions of TCZ-treated patients experienced disease flare than PBO-treated patients across all groups (PMR only, 41.9% vs 57.1%; cranial only, 20.7% vs 47.2%; PMR and cranial, 31.7% vs 81.8%). Annualized flare rate and risk of flare were significantly lower with TCZ vs PBO for patients with cranial symptoms only and both symptoms; they were numerically lower, but did not reach statistical significance, in the smaller group of patients with PMR symptoms only. CONCLUSIONS: TCZ improved clinical outcomes in patients who presented with PMR symptoms only, cranial symptoms only or both at baseline, suggesting that TCZ is effective in patients with GCA regardless of the presenting clinical phenotype.
引用
- Spiera R, Unizony SH, Bao M, et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum. 2021. PMID: 33784598. doi:10.1016/j.semarthrit.2021.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。